Compare FIVN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIVN | HRMY |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2014 | 2020 |
| Metric | FIVN | HRMY |
|---|---|---|
| Price | $27.04 | $35.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 9 |
| Target Price | $26.06 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 2.2M | 856.6K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 364.71 | 7.97 |
| EPS | 0.21 | ★ 0.55 |
| Revenue | ★ $1,149,088,000.00 | $868,453,000.00 |
| Revenue This Year | $11.39 | $19.75 |
| Revenue Next Year | $10.00 | $12.88 |
| P/E Ratio | $121.67 | ★ $65.47 |
| Revenue Growth | 10.28 | ★ 21.51 |
| 52 Week Low | $13.29 | $25.52 |
| 52 Week High | $28.51 | $40.87 |
| Indicator | FIVN | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 62.95 | 52.97 |
| Support Level | $17.66 | $35.05 |
| Resistance Level | N/A | $39.07 |
| Average True Range (ATR) | 1.64 | 1.61 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 94.22 | 56.24 |
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.